Expression of human epidermal growth factor receptor 2 in gastroesophageal cancer with different scoring systems and its relationship with clinicopathological features.
- Author:
Xin JI
1
;
Yi-Qiang LIU
;
Ai-Wen WU
;
Lian-Hai ZHANG
;
Zi-Yu LI
;
Fei SHAN
;
Xiang-Hong LI
;
Jia-Fu JI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; metabolism; pathology; Female; Humans; Immunohistochemistry; Male; Middle Aged; Receptor, ErbB-2; metabolism; Retrospective Studies; Stomach Neoplasms; metabolism; pathology
- From: Chinese Journal of Gastrointestinal Surgery 2011;14(5):356-359
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the expression of human epidermal growth factor receptor 2 (HER2) under different scoring systems in gastroesophageal cancer and its relationship with clinicopathological features.
METHODSClinicopathological data were retrospectively reviewed of 127 patients with gastroesophageal cancer between January and December 2009 in the Department of Surgery at the Cancer Hospital of Peking University. Tumor specimens were collected. The expression of HER2 protein was detected by immunohistochemistry.
RESULTSHER2 positive rate(++/+++) in gastroesophageal cancer was 15.0%(19/127) with both new and traditional immunohistochemical scoring systems, while HER2 strong positive rate(+++) was 10.2%(13/127) and 6.3%(8/127), respectively(P=0.26). Univariate analysis showed that the expression rate of HER2 protein was associated with differentiation and Lauren classification of the tumor. Multivariable analysis showed that TNM staging and tumor differentiation were independently associated with the expression of HER2 protein(both P<0.05).
CONCLUSIONSThere is no change in HER2 positive rate in gastroesophageal cancer between the new and traditional immunohistochemical scoring systems. Expression of HER2 is associated with clinicopathological features in the gastroesophageal cancer.
